AIM:To investigate the expression of perforin and fas-ligand (fas-L) of tumor infiltrating lymphocytes (TILs) in human hepatocellular carcinoma (HCC). METHODS: By in situ hybridization and immunohistochemistry, the perforin and fas-L gene expression of TILs was studied in 20 HCC cases. RESULTS: Positive expression of perforin and fas-L genes was detected in 16 HCC cases. One patient had expression of perforin and fas-L genes in the majority of TILs and survived 1.5 years after tumor resection without HCC relapse.This seems that the presence of a large number of activated T cells might be beneficial for the antitumor immunity. In other cases, less than 10% of TILs were able to express perforin and fas-L genes. CONCLUSION: Although there were a number of T cells in HCC, only few of them were immunoactive and able to kill tumor cells. It seems important to promote further proliferation of these activated T cells in vitro or in vivo.
AIM:To investigate the expression of perforin and fas-ligand (fas-L) of tumor infiltrating lymphocytes (TILs) in humanhepatocellular carcinoma (HCC). METHODS: By in situ hybridization and immunohistochemistry, the perforin and fas-L gene expression of TILs was studied in 20 HCC cases. RESULTS: Positive expression of perforin and fas-L genes was detected in 16 HCC cases. One patient had expression of perforin and fas-L genes in the majority of TILs and survived 1.5 years after tumor resection without HCC relapse.This seems that the presence of a large number of activated T cells might be beneficial for the antitumor immunity. In other cases, less than 10% of TILs were able to express perforin and fas-L genes. CONCLUSION: Although there were a number of T cells in HCC, only few of them were immunoactive and able to kill tumor cells. It seems important to promote further proliferation of these activated T cells in vitro or in vivo.
Authors: D Kägi; F Vignaux; B Ledermann; K Bürki; V Depraetere; S Nagata; H Hengartner; P Golstein Journal: Science Date: 1994-07-22 Impact factor: 47.728
Authors: M B Leger-Ravet; O Devergne; M Peuchmaur; P Solal-Celigny; N Brousse; P Gaulard; P Galanaud; D Emilie Journal: Am J Pathol Date: 1994-03 Impact factor: 4.307
Authors: M R Alderson; T W Tough; T Davis-Smith; S Braddy; B Falk; K A Schooley; R G Goodwin; C A Smith; F Ramsdell; D H Lynch Journal: J Exp Med Date: 1995-01-01 Impact factor: 14.307